SAN FRANCISCO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/DNA?src=hash” target=”_blank”gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced that Emily Leproust, Ph.D.,
CEO and co-founder, will present at the Jefferies 2019 Global Healthcare
Conference on Tuesday, June 4th at 8 a.m. ET.
This presentation will be webcast live and can be accessed by visiting
the “Presentations” page of the investor relations section of the
company’s website here.
A replay of the presentation will be archived for a period of 90 days
following the conclusion of the live event.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.